Logo Image
News
News
Academy
Multimedia
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in MedicineShorts
Conferences
Conference CoverageConference Listing
More
Publications
Pharmaceutical Executive
Partner Perspectives
Resources
Content Engagement HubsEventsSponsored PodcastsSponsored VideosWebcastsWhitepaperseBooks
Event Calendar

Subscribe

  • News
  • Academy
  • Multimedia
  • Conferences
  • Publications
  • Partner Perspectives
  • Resources
  • Event Calendar
  • Subscribe
  • Corporate Communications
    • Press Releases
    • Executive Roundtable
    • Executive Profiles
    • Leadership
  • Direct-to-Consumer
    • Patient Education
    • Healthcare Access
    • Telehealth
  • Emerging Biopharma
    • Partnerships
    • Funding
  • IR Licensing and Partnerships
    • Finance
    • Industry Trends
  • Market Access
    • Patient Access
    • Pricing
    • Strategy
  • Medical Affairs
    • Patient Advocacy
    • Clinical Data
    • Pharmacovigilance
  • Operations
    • Sustainability
    • Technology
    • R&D/Clinical Trials
    • Supply Chain
  • Patient Engagement
    • DE&I
  • Regulatory
    • FDA
    • Legal
    • Global
  • Sales & Marketing
    • Sales Effectiveness
    • Campaigns
    • DTC Marketing
    • Medical Education
Spotlight -
Emerging Pharma Leaders Awards|
Latest Executive Roundtables|
Asembia 2026|
Sales Effectiveness
Advertisement

Mark Talens, Chief Commercial Officier

Advertisement

Articles by Mark Talens, Chief Commercial Officier

Man with short brown hair, black glasses, and shirt/suit jacket talks in front of an PAXAFE blue background

Rethinking Artificial Intelligence within Pharma Supply Chains

ByMark Talens, Chief Commercial Officier,PAXAFE
October 7th 2026

Sponsored

Adding artificial intelligence (AI) to legacy pharma supply chain systems requires auditable human intelligence to fix data and trust gaps.

Advertisement

Latest Updated Articles



    Advertisement
    Advertisement

    Trending on PharmExec

    1

    M&A Roundup: Johnson & Johnson Acquires Ollin Biosciences, Eli Lilly Acquires Calytrix Bio, AmyriAD Therpaeutics Acquires AD04 Alzheimers Program, Sanofi Enters Collaboration with Seawolf Therapeutics

    2

    FDA Approves Klygefa for gMG, Gazyva for Primary Membranous Nephropathy, Igalmi for Agitation Associated with Schizophrenia

    3

    The Hidden Risk in Pharma’s AI Rush

    4

    Pharmaceutical Executive Daily: FDA Approves Three New Therapies

    5

    FDA Pauses Commissioner’s National Priority Voucher Program: Report

    • About
    • Advertise
    • Contact Us
    • Editorial Board
    • Editorial Submission Guidelines
    • Do Not Sell My Personal Information
    • Privacy Policy
    • Terms and Conditions
    Contact Info

    259 Prospect Plains Rd, Bldg H
    Cranbury, NJ 08512

    Brand Logo

    © 2026 MJH Life Sciences®

    All rights reserved.

    Home
    About Us
    News
    Contact Us